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ABSTRACT
Background: Compared with the Taxus® stent, the non-
polymeric paclitaxel-eluting Amazonia® PAX stent shows 
no differences in the occurrence of coronary restenosis or 
clinical events after four months of follow-up. However, the 
performance of the Amazonia® PAX stent in more complex 
cases and with longer angiographic follow-up has not been 
demonstrated. Methods: The PAX-B study was a prospective, 
non-randomised, multicentre study assessing the long-term 
follow-up of patients treated with the Amazonia® PAX 
stent. The primary outcome was late in-stent lumen loss. 
Results: The study included 103 patients with a mean age 
of 61.3  ±  11.4 years; 26.2% were diabetics, 24.3% had 
acute coronary syndromes, and 71.6% had type B2/C lesions. 
Multiple stents were implanted in 4.7% of the patients, and 
angiographic success was achieved in 100% of the cases. 
During hospitalisation, the periprocedural acute myocardial 
infarction rate was 3.9%, and one of these events led to 
target-lesion revascularisation (TLR). At the nine-month 
angiographic follow-up, the median late in-stent lumen 
loss was 0.91 [0.50; 1.21]  mm. The cumulative rates of 
major adverse cardiac events at the six-month, nine-month, 
and 12-month follow-ups were 7.8%, 18.5%, and 21.3%, 
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RESUMO
Seguimento Angiográfico e Clínico Tardio do Novo 
Stent Farmacológico Não Polimérico Liberador de 
Paclitaxel para o Tratamento de Lesões Coronárias 
De Novo: Resultados do Estudo PAX-B
Introdução: O stent farmacológico eluidor de paclitaxel, 
não polimérico, Amazonia® PAX não mostrou diferença na 
reestenose coronária ou eventos clínicos aos 4 meses de 
evolução quando comparado com o stent Taxus®. Entretan-
to, o desempenho do stent Amazonia® PAX em cenários de 
maior complexidade e com seguimento angiográfico mais 
longo ainda não foi demonstrado. Métodos: O Estudo PAX-B 
foi um estudo prospectivo, não randomizado, multicêntrico, 
que avaliou os resultados tardios de pacientes tratados com o 
stent Amazonia® PAX. O desfecho primário foi a perda tardia 
do lúmen intrastent. Resultados: Foram incluídos 103 pacien-
tes com média de idade de 61,3 ± 11,4 anos, 26,2% eram 
diabéticos, 24,3% apresentaram-se com síndrome coronária 
aguda e 71,6% tinham lesões tipo B2/C. Implante de múltiplos 
stents ocorreu em 4,7% dos casos e o sucesso angiográfico 
foi de 100%. Na fase hospitalar, a taxa de infarto agudo do 
miocárdio periprocedimento foi de 3,9%, e um desses eventos 
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respectively, mostly due to TLR. There were no deaths or 
stent thromboses at 12 months. Conclusions: The Amazonia® 
PAX stent showed excellent immediate results and a good 
safety profile. However, angiographic recurrence rates were 
relatively high because of the low efficacy of neointimal 
hyperplasia inhibition.
 
 
 
 
 
 
DESCRIPTORS: Drug-eluting stents. Paclitaxel. Coronary disease. 
Coronary thrombosis.
levou à revascularização da lesão-alvo (RLA). No seguimento 
angiográfico de 9 meses, a mediana da perda tardia do lúmen 
intrastent foi de 0,91 [0,50; 1,21] mm. As taxas cumulativas 
de eventos cardíacos adversos maiores nos seguimentos de 6 
meses, 9 meses e 12 meses foram, respectivamente, de 7,8%, 
18,5% e 21,3%, principalmente em decorrência de RLA. 
Não se observou morte ou trombose de stent em 12 meses. 
Conclusões: O stent Amazonia® PAX demonstrou excelentes 
resultados imediatos e alto perfil de segurança. Entretanto, as 
taxas de recorrência angiográfica foram relativamente altas, 
em razão da pouca eficácia na inibição da formação de 
hiperplasia neointimal.
DESCRITORES: Stents farmacológicos. Paclitaxel. Doença das 
coronárias. Trombose coronária.
I nitially, first-generation drug-eluting stents (DES) with durable polymers were shown to be effective in the treatment of selected coronary lesions due to the 
significant reduction in neointimal hyperplasia formation, 
restenosis and, consequently, the need to perform target 
lesion revascularisation (TLR), when compared to bare-
metal stents (BMS).1–3 However, despite the remarkable 
effectiveness of these devices in different scenarios,4 con-
cerns related to their safety profile and long-term safety 5 
have led to the development of new technologies, aim-
ing to optimise results.6–11
Specifically, late stent thrombosis post-DES has been 
considered a rare and multifactorial phenomenon,12,13 
involving delayed strut endothelialisation and heal-
ing of the treated segment.14,15 Previous pathological 
studies demonstrated that the presence of durable 
polymer debris was associated with inflammation 
and eosinophil infiltration in the artery wall and is 
thus a potentially thrombogenic factor.15,16 Therefore, 
non-polymeric DES were developed as an alternative 
to earlier generation DES, which used polymers as a 
drug carrier system.6,17,18
The Amazonia PAX® device (Minvasys SAS – Gennevil-
lieres, France) is a DES that incorporates a low profile 
platform and an antiproliferative agent, paclitaxel, 
which is applied directly to the surface of the device 
without the use of a polymer. Recently published data 
from the initial study on the device (vs. Taxus® Liberté 
DES, Boston Scientific – Natick, MA, USA) showed 
no significant differences in the occurrence of angio-
graphic restenosis at four months or clinical events 
up to 12 months in a small sample of patients from a 
single-centre study.19 However, the performance of the 
Amazonia PAX® stent in more complex scenarios, with 
more patients and over longer angiographic follow-up 
has not been determined. The present study aimed to 
report the nine-month angiographic follow-up and the 
long-term clinical outcomes of patients treated with the 
Amazonia PAX® stent in a prospective, multicentre study.
METHODS
Study protocol and population
The PAX-B study was a prospective, nonrandomised, 
multicentre, international study that aimed to evaluate the 
long-term clinical and angiographic outcomes of patients 
with obstructive coronary artery disease treated with the 
Amazonia PAX® stent in nine clinical centres, of which 
seven were located in Europe and two were located in 
Brazil. The study population included patients aged ≥  18 
years, with stable or unstable angina and/or a stress test 
positive for ischaemia. The angiographic inclusion criteria 
were the presence of a de novo coronary lesion with 
stenosis of ≥  50% and a length of ≤  20  mm by visual 
analysis, located in a natural coronary artery, with a refer-
ence diameter between 2.5 mm and 3.5 mm, as well as a 
favourable anatomy for percutaneous coronary intervention 
with stent implantation. The main exclusion criteria were 
acute myocardial infarction within < 72 hours of the index 
procedure; renal failure with basal serum creatinine ≥ 2 mg/
dL; previous percutaneous coronary intervention of the target 
lesion; previous coronary intervention of the target vessel 
within nine months of the index procedure; cardiogenic 
shock; cerebrovascular accident; lesions located in a coro-
nary bifurcation, left main coronary artery or saphenous 
vein bypass graft; calcification and/or significant tortuosity; 
total occlusion; left ventricular ejection fraction of < 30%; 
and hypersensitivity or contraindication to aspirin and/or 
thienopyridine (clopidogrel).19 According to the protocol, 
treatment of up to two lesions per patient was permitted, 
as long as a single lesion was treated per target vessel.
The study was in conducted accordance with the 
Declaration of Helsinki, was approved by the Ethics 
Committee of the participating clinical centres, and 
complied with the mandatory regulations and require-
ments of the Comissão Nacional de Ética em Pesquisa 
(Brazilian National Research Ethics Commission, CONEP). 
Furthermore, all participating patients signed an informed 
consent prior to study inclusion.
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Device description
The design, profile, and characteristics of the Ama-
zonia PAX® stent have been detailed elsewhere.19 In 
summary, this device incorporates a low-profile metallic 
cobalt-chromium platform, with a thickness of 73 µm, 
an open-cell modular design, and an antiproliferative 
agent, paclitaxel, which is applied directly to the ablu-
minal surface of the stent struts by a microdrop spray 
crystallisation process. This procedure only adds 5 µm 
to strut thickness and aims to ensure the integrity of 
the drug and a controlled release profile.
Procedure
The percutaneous procedures were performed ac-
cording to current guidelines,20 and the final procedure 
was left to the surgeon’s discretion. Direct stent implan-
tation was allowed. The implantation of an additional 
stent in the target lesion was allowed if dissection 
and/or the need for complete coverage of the lesion 
and the treatment of multiple lesions (maximum of 
two in distinct target vessels) was permitted according 
to the protocol. Notably, only patients treated exclu-
sively with Amazonia PAX® stents were considered for 
the final analysis of the PAX-B study. Amazonia PAX® 
stents with diameters of 2.5 mm, 3 mm, and 3.5 mm, 
and extensions of 8 mm, 12 mm, 16 mm, 20 mm, and 
24  mm were available for the study.
Dual antiplatelet therapy consisted of the adminis-
tration of aspirin (100–325 mg/day) and thienopyridine 
(75 mg/day of clopidogrel). In case of failure or intoler-
ance, the administration of 250 mg of ticlopidine two 
times daily was allowed. The administration of clopidogrel 
was started at least 24 hours before the procedure, and 
a loading dose of 300  mg (or 500  mg of ticlopidine) 
was recommended. After the procedure, aspirin therapy 
was maintained indefinitely, and thienopyridine therapy 
was maintained for at least 12 months, as currently 
recommended.20 Regarding antithrombin therapy dur-
ing the procedure, unfractionated heparin (UFH) was 
administered intravenously at a dose of 70–100  U/kg 
to maintain an activated coagulation time of >  250 
seconds (or >  200 seconds in case of glycoprotein 
IIb/IIIa inhibitor use, which was administered at the 
surgeon’s discretion).
Regarding additional tests, a 12-lead electrocardio-
gram was obtained before, immediately after, and 24 
hours after the procedure. Laboratory tests for cardiac 
enzymes (creatine phosphokinase and creatine kinase 
MB-fraction) were conducted pre-procedure (< 72 hours) 
and every six to eight hours during the first 24 hours 
after the procedure or until hospital discharge.
Outcomes and definitions
The primary study endpoint was late lumen loss 
in the in-stent segment, as assessed by a quantitative 
coronary angiography analysis at the nine-month follow-up. 
Secondary endpoints were target vessel failure, TLR and 
target-vessel revascularisation (TVR) at the nine-month 
follow-up, immediate success (of the device, lesion, 
and procedure), major adverse cardiac events (MACE), 
and binary restenosis assessed by quantitative coronary 
angiography at the nine-month follow-up. All deaths 
were considered to be cardiac unless a noncardiac cause 
could be clearly established by clinical evaluation or 
anatomopathological studies. Target vessel failure was 
defined as the composite endpoint of TVR, myocardial 
infarction, and cardiac death. MACE were defined by 
the composite endpoint of death, myocardial infarc-
tion, and target-lesion revascularisation (percutaneous 
or surgical). Stent thrombosis was defined according 
to the criteria of the Academic Research Consortium.21 
Device success was defined as the successful delivery 
and implantation of the study stent at the lesion site. The 
lesion success (angiographic) was defined by achieving 
a stenosis diameter (SD) of < 50% in the target lesion 
after the procedure. Procedural success was defined as 
lesion success without the occurrence of MACE during 
the index hospitalisation.
Angiographic analysis
The acquisition of angiographic images occurred 
after the intracoronary administration of nitrate (100–
200 mg) and included two orthogonal projections (> 30 
degrees), which aimed to optimise the visualisation of 
the target lesion. The qualitative and quantitative an-
giographic analyses were performed serially pre- and 
post-procedure and at the nine-month follow-up, and 
were independently analysed by the Angiographic Analy-
sis Laboratory of the Cardiovascular Research Centre 
(São Paulo, SP, Brazil). Overall, the qualitative analysis 
followed previously established definitions, including 
characteristics of the vessel, lesion morphology, and 
coronary flow.22 The analyses of quantitative coronary 
angiography were performed off-line by surgeons who 
were experienced with the methods and blinded to 
procedural data, using a computerised quantitative 
analysis system with semi-automatic detection for 
luminal borders, which has been validated, is com-
mercially available (QAngio® XA, version 7.2, Medis 
– Leiden, the Netherlands), and incorporates a tool to 
perform the segmental analysis. Lesion extension was 
delimited by the distance between points immediately 
before and after the target-stenosis considered free of 
atheromatous processes, i.e., the transition between the 
stenotic segment and the normal references (5–10 mm). 
The minimal lumen diameter (MLD) and the reference 
vessel diameter (RVD) were used to calculate SD us-
ing the formula: SD (%) = [1 − (MLD/RVD)] x 100. 
Immediate gain was defined as the difference in MLD 
pre- and post-procedure (MLD post-procedure minus 
pre-procedural MLD). Late lumen loss was defined as 
the difference in MLD after the procedure and at the 
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long-term follow-up (MLD post-procedure minus MLD 
at the nine-month follow-up). Binary restenosis was 
defined as the presence of SD ≥  50% in the treated 
segment at the long-term follow-up and was classified 
as focal (< 10 mm) or diffuse (≥ 10 mm). The restenoses 
were also classified according to Mehran.23 Quantitative 
variables were reported in the in-stent and intra-segment 
segments, which incorporates the in-stent segment and 
5  mm of the borders.6
Clinical follow-up and database
Clinical follow-up was planned at one month, six 
months, nine months, and 12 months after the proce-
dure and annually for up to five years. The follow-up 
consisted of medical consultations or telephone contact, 
performed in accordance with a pre-defined protocol. 
At the nine-month follow-up, an angiographic study 
was mandatory. The electronic data capture system that 
was used was based on an Oracle platform (Redwood 
Shores, CA, USA), with restricted access through personal 
passwords. In 100% of the cases, the data were verified 
to correct any discrepancies or inconsistent informa-
tion through remote monitoring. Physical monitoring 
(in person) was performed in a sample of 15% of the 
cases, selected at random. For both remote and physical 
monitoring, the procedures were the responsibility of 
the study’s data coordinating centre. All adverse events 
were verified directly with the source documentation 
and were subsequently adjudicated by an independent 
clinical events committee consisting of three profession-
als experienced in clinical and invasive cardiology. For 
the current analysis, the results of the procedure, the 
angiographic restudy at nine months, and the clinical 
follow-up up to 12 months are reported.
Statistical analysis
Categorical variables are shown as absolute num-
bers and frequencies. Quantitative variables are shown 
as mean and standard deviation (± SD) or median and 
interquartile range [25%; 75%].
RESULTS
A total of 103 patients were enrolled between 
December, 2008 and November, 2009. The baseline 
characteristics are shown in Table 1. Overall, the mean 
age was 61.3 ± 11.4 years, 26.2% were diabetics, and 
41.7% had a previous myocardial infarction. Regard-
ing the clinical presentation, approximately half of the 
patients had stable angina.
Angiographic data are shown in Table 2. In to-
tal, 127 lesions were included (1.24  ±  0.43 lesions 
per patient) and the anterior descending artery was 
the target vessel most often treated (39.4%). Ad-
ditionally, high-complexity lesions (type B2/C) were 
found in most cases (71.6%). During the procedure, 
radial access was used in 46.6% of the cases, and 
a second stent in the target lesion was implanted in 
4.7% of the cases (Table 3). At the end of the PCI, 
both angiographic success and device success were 
achieved in 100% of the cases.
Table 4 shows the pre- and post-procedure results 
of the quantitative coronary angiography analysis. At 
the nine-month angiographic follow-up (92.1% of the 
lesions), the medians of the late intra-segment and in-
stent lumen loss were 0.64 [0.32; 0.92] mm and 0.91 
[0.50; 1.21]  mm, respectively (Table 5). The rate of 
restenosis was 19.7%, and most recurrent cases were 
of focal in-stent type (Table 6).
Regarding clinical events while in the hospital, 
four patients (3.9%) had periprocedural myocardial 
infarctions (all without Q-wave), and one of these 
events led to TLR. In this case, the patient returned 
to the haemodynamics laboratory on the same day 
of the index procedure since he exhibited ischaemic 
symptoms after the procedure. At the angiographic 
assessment, a dissection was observed at the border 
of the previously implanted stent, which was treated 
with an additional stent implantation, overlapping 
with the struts of the other stent. Between hospital 
discharge and 30 days after the procedure, there was 
one instance of new myocardial infarction (non-Q). 
Figure 1 shows the cumulative rates of adverse events 
after hospital discharge up to the 12-month follow-up 
TABLE 1 
Baseline Clinical Characteristics
Variable
n = 103  
patients
Mean age, years
Female gender, n (%)
Diabetes mellitus, n (%)
Insulin in use
Systemic arterial hypertension, n (%)
Dyslipidemia, n (%)
Smoking, n (%)
Previous AMI, n (%)
Previous PCI, n (%)
Previous CABG, n (%)
Clinical presentation, n (%)
Silent ischemia
Stable angina
Unstable angina
61.3 ± 11.4
24 (23,3)
27 (26.2)
5 (4.8)
74 (71.8)
64 (62.1)
23 (22.3)
43 (41.7)
20 (19.4)
0
29 (28.1)
49 (47.6)
25 (24.3)
AMI = acute myocardial infarction; PCI = percutaneous 
coronary intervention; CABG = coronary artery bypass graft.
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TABLE 2 
Angiographic Data
Variable
n = 127  
lesions
Target-vessel, n (%)
 ADA
 Cx
 RCA
Location (segment), n (%)
 Ostial
 Proximal
 Medium
 Distal
Type of lesion (ACC/AHA), n (%)
 A
 B1
 B2
 C
50 (39.4)
44 (34.7)
33 (26)
1 (0.8)
47 (37)
64 (50.4)
15 (11.8)
13 (10.2)
23 (18.1)
84 (66.1)
7 (5.5)
ACC = American College of Cardiology; AHA = American 
Heart Association; RCA = right coronary artery; Cx = circumflex 
artery; ADA = anterior descending artery.
TABLE 3 
Procedure
Variable
n = 103 patients
(127 lesions)
Radial access, n (%)
Pre-dilation, n (%)
 Nominal balloon extension, mm 
 Nominal balloon diameter, mm
 Balloon insufflation pressure, atm
 Implanted study stent, n (%)
 Nominal stent extension, mm
 Nominal stent diameter, mm
 Stent release pressure, atm
Additional implanted stent, n (%)
Post-dilation, n (%)
 Nominal balloon extension, mm
 Nominal balloon diameter, mm
 Balloon insufflation pressure, atm
Final TIMI flow grade 3, n (%) 
48/103 (46.6)
54/127 (42.5)
13.9 ± 3.2
2.68 ± 0.88
10.6 ± 2.9
127/127 (100)
16.9 ± 3.9
3.02 ± 0.37
13.5 ± 3.5
6/127 (4.7)
73/127 (57.5)
11.5 ± 2.6
3.21 ± 0.41
16.9 ± 3.8
127/127 (100)
TIMI = thrombolysis in myocardial infarction.
TABLE 4 
Pre- and Post-procedural Quantitative Angiography
Variable
n = 127  
lesions
Pre-procedure
Lesion extension, mm
RVD, mm
MLD, mm
SD, %
Post-procedure
RVD, mm
Intra-segment
 MLD, mm
 SD, %
 Immediate gain, mm
Intrastent
 MLD, mm
 SD, %
 Immediate gain, mm
Baloon:artery ratio
12.1 [9.9; 15.8]
2.92 [2.64; 3.21]
0.70 [0.43; 1.00]
74.8 [64.8; 86.0]
2.95 [2.70; 3.30]
2.46 [2.22; 2.77]
15 [10.3; 21.1]
1.74 [1.40; 2.06]
2.79 [2.53; 3.11]
5.7 [3.6.; 8.5]
2 [1.72; 2.40]
1.10 [1.06; 1.16]
MLD = minimal lumen diameter; RVD = reference vessel 
diameter; SD = stenosis diameter.
TABLE 5 
Angiographic follow-up at nine months
Variable n = 117 lesions
RVD, mm
Intra-segment
 MLD, mm
 SD, %
 Late lumen loss, mm
Intrastent
 MLD, mm
 SD, %
 Late lumen loss, mm
2.81 [2.41; 3.07]
1.84 [1.40; 2.25]
31.7 [21.5; 44.7]
0.64 [0.32; 0.92]
1.94 [1.41; 2.30]
27.3 [16.4; 41.8]
0.91 [0.50; 1.21]
MLD = minimal lumen diameter; RVD = reference vessel 
diameter; SD = stenosis diameter. 
(100% of patients). In general, rates of target vessel 
failure (22.3%) and MACE (22.3%) after one year 
were directly related to the rates of TLR and TVR. 
There were no deaths from stent thrombosis or any 
other cause during follow-up.
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DISCUSSION
In this prospective, multicentre, international registry, 
the non-polymeric paclitaxel-eluting Amazonia PAX® stent 
showed excellent immediate results (device/angiographic 
success of 100% and procedural success of 96.1%), 
as well as sustained safety after one year. However, 
its clinical effectiveness was lower than that reported 
for other DES, with and without polymers.1–3,7–11,24–28 
Notably, the angiographic findings in the long-term 
follow-up of the PAX-B study are similar to results 
reported with other previously tested non-polymeric 
paclitaxel-releasing stents,6 which also confirms that the 
Amazonia PAX® stent is less effective than the Taxus® 
Liberté paclitaxel-releasing stent with durable polymer 
at suppressing neointimal proliferation.19
In general, first-generation DES, such as Cypher® 
(Cordis – Miami  Lakes, USA) and Taxus®, demon-
strated remarkable and sustained clinical effective-
ness.29 However, the durable polymeric components 
used as drug carriers in these devices were shown 
to cause an intense local inflammatory response,30,31 
which has been associated with recurrence and late 
thrombotic phenomena.15,16,32,33 Thus, the second 
generation of DES introduced more biocompatible 
polymers and systems with biodegradable poly-
mers.7,8,10,11 Recent studies suggest that these devices 
have an improved safety profile compared to the 
first generation of DES, without compromising their 
clinical effectiveness.34,35 Nonetheless, the develop-
ment of DES without polymers (third-generation DES) 
could, at least in theory, offer additional advantages, 
such as a) the prevention of adverse effects due to 
the prolonged or temporary presence of polymeric 
residues; b) the optimisation of vascular healing; c) 
the sustained integrity of the stent surface; and d) the 
maintenance of dual antiplatelet therapy for shorter 
periods.36 However, the removal of the polymer from 
the DES may overly compromise its effectiveness, as 
the polymer is responsible not only for carrying the 
drug, but also for controlling release kinetics.6 Previous 
studies have shown that using a non-polymeric stent 
coating is safe and may lead to a dose-dependent 
decrease in restenosis rates; however, these studies 
have also demonstrated that the critical aspect is the 
elution profile of the antiproliferative drug.6,17,18 In 
the current analysis, the relatively small sample size 
(n = 103) notwithstanding, impairment in safety was 
not observed, despite the high prevalence of complex 
cases and lesions, including an absence of death 
or stent thrombosis up to the 12-month follow-up. 
However, the unexpectedly high rates of recurrence 
indicate the technological challenge of maintaining 
effectiveness in the absence of a polymer.
In the prospective, randomised, multicentre study 
DELIVER, which included 1,043 patients, the non-
polymeric, paclitaxel-releasing DES Achieve® (Guidant 
Corp. – Santa Clara, CA, USA) presented a mean late 
in-stent lumen loss of 0.81  ±  0.60  mm at the eight-
month follow-up (vs. 0.98  ±  0.57  mm in the control 
group, treated with BMS, P  =  0.003); however, this 
difference did not translate into significant decreases 
in the rates of binary restenosis or TLR. In this case, 
the device in the active group (Achieve® stent) received 
a coating of paclitaxel at a dose of 3  mg/mm2 of the 
stent surface area.6 Similar to the first generation Taxus® 
Liberté DES, which incorporates a durable polymer, the 
paclitaxel dose is rather low (1 mg/mm2 of the stent surface 
area).3 Nevertheless, preclinical studies have estimated a 
significant loss of the antiproliferative agent (up to 40% 
of the total) during stent delivery with the nonpolymeric 
device when compared to < 10% of drug elution in 30 
days with the Taxus® stent.3,6 With the Amazonia PAX® stent, 
tested in the PAX-A and PAX-B studies, the medians of late 
in-stent lumen loss were 0.77 [0.47; 1.05] mm (four months) 
and 0.91 [0.50; 1.21] mm (nine months), respectively. It 
is noteworthy that the paclitaxel dose (or concen-
tration) was 0.67  µg/cm2 of the stent surface area, 
TABLE 6 
Binary restenosis
Angiographic follow-up at  
nine months
n = 117  
lesions
Total, n (%) 23 (19.7)
Mehran’s classification,23 n
Type 1A 0
Type 1B 0
Type 1C 18
Type 1D 0
Type 2 2
Type 3 0
Type 4 3
TVR
%
 o
f p
at
ie
nt
s
30 days
40
30
20
10
0
6 months 9 months 12 months
18.5 18.5
21.3 21.3
7.8 7.8
1 0 0 01 1 1 0 10
TVF Death AMI
Figure 1 – Cumulative adverse events after hospital discharge up to 
12 months of clinical follow-up (n = 103). TVF = target vessel failure, 
AMI = acute myocardial infarction, TVR = target vessel revascularisation.
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with 33%–52% of the drug being released within 
eight hours; 55%–75%, within a week; and 100%, in 
45 days.19 Thus, the kinetics of drug release appear to 
explain, at least in part, the greater efficacy observed 
with polymeric vs. non-polymeric DES, despite the 
use of the same drug (in this case, paclitaxel) and 
a reduced dose.6,19 Greater efficacy has also been 
observed with stents releasing drugs from the ‘limus’ 
class.1,2,7,11,24,25 Late angiographic results with the 
non-polymeric sirolimus-releasing DES Yukon® (Trans-
lumina GmbH, Hechingen, Germany) demonstrated 
relatively lower efficacy when compared with re-
sults of the first generation sirolimus-releasing DES 
Cypher®. In the prospective, randomised study, Intracoro-
nary Stenting and Angiographic Restenosis (ISAR-TEST), 
which included 450 patients, the mean late in-stent 
lumen loss was 0.48 ± 0.61 mm with the Yukon® stent 
(vs. 0.48 ± 0.58 mm with the Taxus® stent).24 Similarly, 
in the ISAR-TEST 3, which compared three sirolimus-
eluting stents, including non-polymeric, biodegrad-
able polymer and durable polymer systems (Cypher®), 
the late in-stent lumen loss was 0.47  ±  0.56  mm vs. 
0.17  ±  0.45  mm vs. 0.23  ±  0.46  mm, respectively.37
Alternatives tested in non-polymeric DES have 
included the incorporation of nonpolymeric carrier 
components and the structural modification of metal 
surfaces. The VESTAsync system (MIV Therapeutics, 
Atlanta, GA, USA) has a microporous hydroxyapatite 
coating that carries the drug sirolimus at a reduced 
dose (approximately 40% of the dose used in the 
Cypher® stent). In the initial study in humans (n = 15), 
the late in-stent lumen loss was 0.30  ±  0.25  mm at 
four months and 0.36  ±  0.23  mm at nine months. 
Corres pondingly, the obstruction volume percentage 
with intracoronary ultrasound was 2.8 ± 2.2% at four 
months and 4 ± 2.2% at nine months. It is important 
to highlight that the VESTAsync stent had a drug-elution 
profile similar to that of the Cypher® stent, with total 
release attained at 90 days.25,28 Additionally, the results 
of a new nonpolymeric system using active carrier 
substances released from a ‘bioinductor’ surface (Cre8, 
CID – Saluggia, Italy) have been recently reported. In 
this prospective randomised study (n = 323), the non-
polymeric stent Cre8, which releases a ‘limus’ drug, 
showed a late in-stent lumen loss at six months of 
0.14  ±  0.36  mm vs. 0.34  ±  0.40  mm for the Taxus® 
Liberté stent (P  <  0.0001).26 Finally, the BioFreedom® 
stent (Biosensors International – Singapore) incorporates 
a technology that uses a modified abluminal metal 
surface and does not use a polymer, resulting in a 
microporous structure that allows adhesion and the 
release of the antiproliferative agent Biolimus A9. In 
the prospective, randomised, BIOFREEDOM study, 182 
patients were randomised into three groups and divided 
into two cohorts according to an angiographic restudy 
at four months (n  =  75) or 12 months (n  =  107). At 
four months, the median values of late in-stent lumen 
loss was 0.08 [0.02; 0.14] mm, 0.12 [0.07; 0.25] mm 
vs. 0.37 [0.14; 0.50] mm for the BioFreedom standard 
dose, the BioFreedom reduced dose, and the Taxus® 
Liberté, respectively; at 12 months, the values were 
0.17 [0.09; 0.39] mm, 0.22 [0.17; 0.66] mm vs. 0.35 
[0.22; 0.57]  mm, respectively (P  =  0.001 for non-
inferiority in the comparison of the standard dose 
BioFreedom group vs. Taxus®).27 Notably, both the 
Cre8 and the BioFreedom stents showed efficacy that 
was relatively superior to that of other reported non-
polymeric DES.26,27 Possible reasons for the improved 
efficacy include the use of the ‘limus’ drug family, 
which has demonstrated superiority in inhibiting 
neointimal hyperplasia in relation to other classes 
of drugs, including paclitaxel.38 Moreover, the Cre8 
system has drug release kine tics that are similar to 
the first- and second-generations polymeric DES.26 In 
contrast, approximately 90% of the drug is released 
within 48 hours after BioFreedom implantation;27 how-
ever, the drug release kinetics do not appear to have 
an impact on efficacy, as observed in other systems. 
It is speculated that this effect is probably due to the 
high lipophilicity of the drug Biolimus A9 (ten times 
greater than that of sirolimus), thus ensuring optimal 
drug absorption and a longer-lasting antiproliferative 
effect. In the case of the Amazonia PAX® stent tested 
in the present study, a new model, which utilizes 
a new carrier and release technology for the drug 
sirolimus based on nanoparticle encapsulation techno-
logy (‘LEX’), has been developed (preclinical studies 
are in progress). This new model should increase the 
effectiveness in inhibiting neointimal hyperplasia for 
that system (R. Costa, personal communication, TCT 
2011. San Francisco, CA, USA).
CONCLUSIONS
In this prospective, multicentre, international 
registry, the new drug-eluting, non-polymeric paclita-
xel-releasing Amazonia® PAX stent showed excellent 
immediate results and a high safety profile, including 
the absence of death or stent thrombosis after one year 
of follow-up. However, recurrence rates were relatively 
high because of the low effectiveness of neointimal 
hyperplasia inhibition.
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